A Phase I trial of WP1732 for treatment of pancreatic cancer
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2018
At a glance
- Drugs WP 1732 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Moleculin Biotech
- 01 Dec 2018 New trial record
- 28 Nov 2018 According to a Moleculin Biotech media release, an Investigational New Drug (IND) application with the FDA is expected to file in 2019.
- 15 Nov 2018 According to a Moleculin Biotech media release, the company is planning a Pre-Investigational New Drug (IND) Meeting to finalize IND filling to initiate this trial.